Objective-To evaluate the effectiveness of long-term angiotensin (Ang) (1-7) treatment to inhibit the progression of atherosclerosis in apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice. (1-7) is a heptapeptide fragment that has been proposed to counterregulate the Ang II proatherogenic effects. The effect of long-term 4-week Ang (1-7) treatment on both inhibition of atherosclerotic lesion development and improvement of endothelial function was examined in apolipoprotein E Ϫ/Ϫ mice that had been fed an atherogenic high-fat (21%) diet for 16 weeks. Chronic Ang (1-7) treatment significantly improved endothelial function, an effect reversed with either angiotensin type 2 (AT 2 ) or Mas receptor blockade. In these vessels, Ang (1-7) treatment significantly decreased superoxide production and increased endothelial nitric oxide synthase immunoreactivity when compared with vehicle treatment. These effects were blocked by both AT 2 and Mas receptor antagonists. Lesion development, assessed as both fatty deposits (oil red O) and intima to media ratio, was also significantly decreased with Ang (1-7) treatment compared with respective controls. Cotreatment with either AT 2 or Mas receptor antagonists reversed Ang (1-7)-mediated reduction in lesion development. (1-7) treatment caused both vasoprotection, via improvement in endothelial function, and atheroprotection, with a reduction in lesion progression in a model of atherosclerosis. These effects appear to be mediated by the restoration of nitric oxide bioavailability and involve a complex interaction of both Mas and AT 2 receptors. (Arterioscler Thromb Vasc Biol. 2010;30:1606-1613.)
There is evidence that other Ang peptide fragments may bind to non-AT 1 R-binding sites to produce effects that counterregulate those mediated by the AT 1 R. One such peptide fragment is the heptapeptide Ang (1-7), which may contribute to the antiatherogenic effects mediated by AT 1 R antagonists and angiotensin-converting enzyme (ACE) inhibitors, with Ang (1-7) plasma levels reported to increase in the presence of these drugs. 14 -17 Formed from either Ang 1 or Ang 2 via actions of either endopeptidases, carboxypeptidase P or ACE2, a homolog of ACE, 18, 19 Ang (1-7) inhibits neointimal formation in stent-implanted rats, 20 improves endothelial function in Wister rats, 21 and activates endothelial nitric oxide synthase (eNOS) in Chinese hamster ovary cells. 22 Recently, it has been suggested that Ang (1-7) mediates its effects by acting as an agonist at the Ang (1-7)/Mas receptor (MasR), [21] [22] [23] although other data suggest that Ang (1) (2) (3) (4) (5) (6) (7) may also act at the AT 2 R 24 or by antagonizing the AT 1 R. 25 These protective effects of Ang (1-7) appear to involve stimulation of NO, bradykinin, and prostaglandin I 2 . 21, 22, 24 However, the long-term effects of Ang (1) (2) (3) (4) (5) (6) (7) in the setting of atherosclerosis are largely unknown. Therefore, this study aimed to investigate the effect of long-term Ang (1-7) infusion on endothelial dysfunction and the development of atherosclerotic lesions using the apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mouse model of atherosclerosis.
Methods
Male B6 ApoE Ϫ/Ϫ mice were obtained at the age of 5 weeks and weighed between 25 and 35 g when the experiments were performed. At the age of 6 to 8 weeks, the mice began receiving a high-fat diet containing 21% fat and 0.15% cholesterol for 12 weeks before treatment and during the subsequent 4-week treatment period. Mice were treated subcutaneously via osmotic minipumps with 1 of the following: vehicle (NaCl, 0.15 mol/L); Ang (1-7) alone (24 or 48 g/kg per hour); Ang (1-7) (24 g/kg per hour), in combination with either an AT 2 R antagonist, PD123319 (10 mg/kg per day), or a MasR antagonist, A779 (48 g/kg per hour); PD123319 (10 mg/kg per day) or A779 (48 g/kg per hour) alone. A group of age-/diet-controlled wild-type (WT) C57BL/6J mice were included and received vehicle treatment only.
Systolic blood pressure was measured by tail-cuff plethysmography. The heart and the whole aorta were removed, which was used to assess the effects of Ang (1-7) on vascular reactivity, atherosclerotic lesion development, and NO bioavailability (eNOS and superoxide levels). Detailed methods are described in the supplemental data (available online at http://atvb.ahajournals.org).
Data are given as meanϮSEM unless otherwise indicated.
Results
Ang (1-7) Improved Endothelial-Dependent Vasorelaxation in ApoE ؊/؊ Mice Systolic blood pressure was unaltered by any of the various treatment groups (supplemental Table I ). Vehicle-treated ApoE Ϫ/Ϫ mice demonstrated an attenuated maximal acetylcholine (ACh)induced vasorelaxation response (R max ϭ59.80Ϯ4.55%; nϭ14) compared with vehicle-treated WT mice (R max ϭ87.87Ϯ7.44%; nϭ6) ( Figure 1A ). Long-term infusion of Ang (1) (2) (3) (4) (5) (6) (7) in ApoE Ϫ/Ϫ mice at both 24 g/kg per hour (R max ϭ79.15Ϯ2.90%; nϭ12) and 48 g/kg per hour (R max ϭ75.28Ϯ3.81%; nϭ8) significantly improved endothelial function to a similar extent when compared with vehicle-treated ApoE Ϫ/Ϫ mice ( Figure 1B) ; therefore, only the results from the lower dose of Ang (1-7) (24 g/kg per hour) are reported. The improved endothelial response was significantly attenuated when ApoE Ϫ/Ϫ mice were cotreated with the MasR antagonist, A779 (R max ϭ65.82Ϯ3.92%; nϭ9). Long-term A779 infusion alone had no effect on endothelial function (R max ϭ65.23Ϯ5.86%; nϭ7) ( Figure 1C ). Coinfusion of the AT 2 R antagonist, PD123319, also significantly attenuated the Ang (1-7)-induced vasoprotective effect (R max ϭ67.19Ϯ4.88%; nϭ9). PD123319 treatment alone further exacerbated endothelial function (R max ϭ48.95Ϯ6.69%; nϭ8) ( Figure 1D ). Endothelium-independent vessel relaxation by the NO donor, sodium nitroprusside (SNP), remained unaltered in all the treatment groups (supplemental Table II ). In addition, the Ca 2ϩ ionophore A23187-mediated vasorelaxation in the isolated aorta of Ang (1-7)-treated ApoE Ϫ/Ϫ mice (R max ϭ80.98Ϯ6.89%; nϭ5) demonstrated similar responses to those seen with ACh-induced vasorelaxation, indicating that Ang (1-7) treatment significantly improved 
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endothelial function via a mechanism independent of any effect on muscarinic receptors per se (supplemental Figure IA) . N G -nitro-L-arginine methyl ester completely abolished ACh-mediated vascular relaxation (supplemental Figure IB ) in aorta taken from both vehicle-treated (R max ϭ0.57Ϯ0.56%; nϭ3) and Ang (1-7)-treated (R max ϭ12.33Ϯ7.34%; nϭ5) ApoE Ϫ/Ϫ mice. In addition, 20 min pretreatment with Ang (1-7) of aortic rings taken from age-/diet-matched ApoE Ϫ/Ϫ mice showed no improvement in ACh-mediated vasorelaxation (R max ϭ32.87Ϯ6.42%; nϭ3) (supplemental Figure IC) , unlike that seen with long-term Ang (1-7) treatment ( Figure 1B 
Ang (1-7) Treatment Increased eNOS Immunoreactivity
eNOS expression in aortic cross sections of the thoracoabdominal aorta (the section of aorta immediately adjacent to the aortic sections used for vascular reactivity studies) was examined using immunohistochemical methods in WT and ApoE Ϫ/Ϫ -treated mice ( Figure 2 ). eNOS immunoreactivity was significantly higher in vehicle-treated WT mice (nϭ6) compared with vehicle-treated ApoE Ϫ/Ϫ mice (nϭ12). Longterm Ang (1-7) treatment (nϭ6) significantly increased eNOS immunoreactivity when compared with vehicle-treated ApoE Ϫ/Ϫ mouse aorta (Figure 2A and B). Also, there was no difference in endothelial cell integrity as determined by von Willebrand factor staining (nϭ4) (Figure 2A ). When Ang (1-7) was coinfused chronically in ApoE Ϫ/Ϫ mice with either the AT 2 R (nϭ10) or the MasR (nϭ9) antagonists, eNOS staining intensity was significantly attenuated. Neither PD123319 (nϭ9) nor A779 (nϭ6) had any effect on eNOS expression when used alone ( Figure 2B ).
Ang (1-7) Treatment Increased eNOS Protein Levels
Western blot analysis confirmed that WT mice show greater immunoreactive bands for eNOS (approximately 140 kDa) (nϭ3) when compared with ApoE Ϫ/Ϫ mice (nϭ4). However, long-term Ang (1-7) treatment in ApoE Ϫ/Ϫ mice (nϭ4) significantly increased the density of the immunoreactive bands for eNOS when compared with vehicle treatment ( Figure 2C ), thus indicating a significant increase in eNOS protein expression compared with vehicle treatment ( Figure 2C ).
Ang (1-7) Decreased Superoxide Production
Superoxide was localized and quantified using dihydroethidium staining in the aortic cross sections from the thoracoabdominal region taken from ApoE Ϫ/Ϫ mice from all long-term treatment groups and their age-/diet-matched WT control mice. Intracellular formation of superoxide attained by dihydroethidium oxidation is represented in red and is evident in the endothelium, media, and adventitia ( Figure  3A ). The intensity of fluorescence was quantified and expressed as total fluorescence intensity per area (arbitrary units per square micrometer). Superoxide levels were significantly lower in vehicle-treated WT mice (nϭ7) when compared with vehicle-treated ApoE Ϫ/Ϫ mice (nϭ7). Ang (1-7) treatment in ApoE Ϫ/Ϫ mice (nϭ15) significantly lowered the intensity of fluorescence when compared with vehicle-treated ApoE Ϫ/Ϫ mice. This effect was reversed by cotreatment with either the AT 2 R antagonist (nϭ8) or the MasR antagonist (nϭ8). Neither PD123319 (nϭ6) nor A779 (nϭ7) had any effect on superoxide levels when used alone ( Figure 3B ). 
Ang (1-7) Decreased Superoxide Basal Levels
The L-012 chemiluminescence method was also used to detect superoxide basal levels in abdominal aortic rings taken from ApoE Ϫ/Ϫ mice. Long-term Ang (1-7) treatment (nϭ7) tended to lower superoxide levels when compared with vehicle-treated animals (nϭ6) ( Figure 4A ). Long-term coinfusion of Ang (1-7) with either the AT 2 R (nϭ8) or the MasR (nϭ8) antagonist resulted in superoxide levels that were similar to the vehicle-treated group. To confirm the specificity and source of superoxide, parallel aortic rings were incubated with either superoxide dismutase, 300 U/mL, or the NADPH oxidase inhibitor, diphenyliodonium, 10 mol/L, for a short time. This incubation attenuated the signal in tissues from all treatment groups, indicating that the main source of superoxide was the enzyme NADPH oxidase ( Figure 4B and C).
Ang (1-7) Decreased En Face Lesion Development
The aortic arch and the thoracic aorta were longitudinally cut open and stained en face with oil red O for lipid deposition, after which the lesions were measured as percentage lesion area. WT mice had no lesions; thus, the data were not included. 
Ang (1-7) Decreased Cross-Sectional Lesion Development
WT mice had no lesions present; therefore, data were not included. Long-term Ang (1-7) treatment significantly de- 
Lipid Analysis
ApoE Ϫ/Ϫ mice (nϭ5) eating a high-fat diet exhibited significantly elevated plasma levels of total cholesterol when compared with either WT mice eating a normal diet (nϭ6) or a high-fat diet (nϭ6) at the same age. In ApoE Ϫ/Ϫ mice, long-term Ang (1-7) treatment (nϭ5) had no effect on these lipid levels when compared with vehicle treatment (nϭ5) (supplemental Table III ).
The plasma Ang II and Ang (1-7) levels were unchanged after long-term Ang (1-7) (24 g/kg per hour) treatment (supplemental Table IV ).
Discussion
To our knowledge, we demonstrated for the first time that long-term Ang (1-7) treatment produces vasoprotective and atheroprotective effects in the ApoE Ϫ/Ϫ mouse model of atherosclerosis. This was evidenced by improved endothelial function as the result of an increase in NO bioavailability as Ang (1-7) increased eNOS expression and protein levels and decreased superoxide levels; these results translated into antiatherosclerotic effects, mediated by both the Ang (1-7)/ MasR and the AT 2 R.
By using an infusion dose based on previous studies 20, 21, 26, 27 that showed Ang (1-7) improved endothelial function in other settings, we report that Ang (1-7) significantly improved endothelial function in ApoE Ϫ/Ϫ mice when it was administered for a period of 4 weeks. Moreover, this effect was independent of agonist used to elicit endotheliumdependent relaxation (ACh or A23187), and long-term Ang (1-7) treatment was obligatory for improved endothelial function because short-term treatment with this peptide was ineffective. We performed these functional measurements using abdominal aortas because they were previously shown to exhibit greater endothelial dysfunction than thoracic aortas from ApoE-deficient mice. 28 However, we did not determine if similar Ang (1-7)-induced changes occur in other vascular regions.
The effects mediated by Ang (1-7) do not involve any direct effect on systolic blood pressure. Researchers 10, 29, 30 have previously reported an improvement in endothelial function in ApoE Ϫ/Ϫ mice with a variety of treatments that have not had any effect on systolic blood pressure; this may reflect that their normotensive status, and basal blood pressure is less sensitive to vasodilator activity. Endothelial dysfunction is associated with the early stages of atherosclerosis and is considered an initiator of its progression. 31 In this context, we have also demonstrated striking inhibition of further lesion development measured via 2 methods. Both lipid deposition and luminal encroachment were significantly inhibited, correlating with the reversal of endothelial dysfunction. This antiatherosclerotic effect of Ang (1-7) most likely reflects prevention of lesion development, which occurs over this time line, rather than regression of existing lesions; thus, proof of principle for an important role for Ang (1) (2) (3) (4) (5) (6) (7) in the setting of atherosclerosis exists.
One potential mechanism accounting for the observed effects is an increase in NO bioavailability. Long-term Ang (1-7) treatment increased eNOS protein levels and immunoreactivity and reduced superoxide production, thus suggesting an overall increase in NO bioavailability. To further support this hypothesis, the potentiation by Ang (1-7) of vascular relaxation was completely abolished in the presence of the NO synthase inhibitor, N G -nitro-L-arginine methyl ester, which is consistent with previous findings. 24, 32 More important, increased eNOS immunoreactivity was not the result of differences in endothelium integrity between treatments because staining using the endothelial cell marker von Wille- brand factor was similar in untreated and Ang (1-7)-treated tissue; however, eNOS immunoreactivity was not performed in the same region as atherosclerosis measurements because it was considered more relevant to correlate changes in vascular function with changes in eNOS expression. The reduction in reactive oxygen species in long-term Ang (1-7)-treated ApoE Ϫ/Ϫ mice (measured via both dihydroethidium staining and lucigenin-enhanced chemiluminescence) appeared to be predominantly superoxide derived from NADPH oxidase because both superoxide dismutase and diphenyliodonium generally reduced basal levels. In Mas Ϫ/Ϫ mice, there is increased blood pressure, evidence of endothelial dysfunction, and increased expression of Nox2, a subunit of the phagocyte-derived NADPH oxidase, when compared with WT mice. 33 This previous study 33 also showed reductions in superoxide dismutase and catalase activity, demonstrating impaired antioxidant ability in Mas Ϫ/Ϫ mice. The current study indicates the functional importance of the MasR in the regulation of oxidative stress; future studies should be aimed at addressing this relationship, including whether Ang (1-7) counterregulates Ang II-driven superoxide production in this model.
There is much speculation as to which receptor Ang (1-7) activates to mediate its effects. Ang (1-7) has been reported to produce cardioprotective effects by binding to the AT 1 R, the AT 2 R, 24,34 -37 or both 32 ; and by inhibiting ACE. 38 However, with the discovery of the G-protein-coupled receptor Mas, suggested to be a functional Ang (1-7) receptor, 23 there are increasing studies showing that Ang (1-7) mediates its effects via the MasR. 23 Ang (1-7) has been shown to have a 13-fold greater binding affinity than Ang II for a non-AT 1 R/AT 2 R in bovine aortic endothelial cells, which was sensitive to blockade by the MasR antagonist, A779. 39 This was reflected in a recent study 40 in which Ang (1-7)-mediated relaxation was equally impaired in WT arteries pretreated with A779 as well as those and isolated from Mas Ϫ/Ϫ mice, indicating a MasRsensitive effect. On the other hand, Ang (1-7) reportedly has a modest affinity for AT 2 Rs in COS-7 cells. 41 In the current study, we have shown that Ang (1-7) can act via both the AT 2 R and the MasR because both PD123319 and A779 abrogated the Ang (1-7)-evoked vasoprotection and atheroprotection and the reciprocal changes in eNOS and superoxide.
Researchers 24, 42, 43 have demonstrated that Ang (1-7) can mediate a number of functional responses via the AT 2 R. In particular, we have demonstrated an AT 2 R-sensitive, but not a MasR-sensitive, vasodepressor response to Ang (1-7) in conscious and spontaneously hypertensive rats. 24 Furthermore, Ang (1-7)-induced vasorelaxation in pig coronary arteries 35 and NO release in bovine aortic endothelial cells 32 were attenuated by the addition of the AT 2 R antagonist, PD123319. In rabbit vascular smooth muscle cells, Ang (1-7)-stimulated arachidonic acid release was partially attenuated by either A779 or PD123319 alone, but was abolished with combined AT 2 R and MasR inhibition. 44 In addition, 2 independent studies, 45, 46 using either Ang (1-7) or the Ang (1-7) nonpeptide mimetic AVE 0991, demonstrated that Ang (1-7)-stimulated NO release in bovine aortic endothelial cells was more sensitive to AT 2 R inhibition (approximately 90%) than MasR inhibition with A779 (approximately 50%), again implicating multiple receptor functions. Moreover, AT 1 R blockade also caused partial inhibition of Ang (1-7)-mediated NO release. 32, 45 In this context, the MasR may act as a physiological antagonist of the AT 1 R in mammalian transfected cells via hetero-oligomerization of the MasR and the AT 1 R. 25 Thus, there is much precedence that Ang (1-7) is able to stimulate multiple Ang receptor subtypes, although the exact mechanism of how this occurs is not entirely clear. Interestingly, although Ang (1-7) appears to act via the MasR in many in vitro/ex vivo settings, 23 this selectivity is lost in vivo. 46 In the current study, PD123319 alone further exacerbated the endothelial dysfunction; although it did not modify eNOS. Thus, functional antagonism of AT 2 R-mediated NO release may play a role in the attenuated effect of Ang (1) (2) (3) (4) (5) (6) (7) in the presence of the AT 2 R antagonist. However, this possibility regarding endothelial dysfunction does not affect interpretation of PD123319 in subsequent experiments because it had no basal effect on all other indices, which implies that endogenous activation of AT 2 R was subthreshold.
Regarding the role of AT 2 R in atherosclerosis, there are both positive and negative reports. AT 2 R-mediated antiatherosclerotic effects have been reported because AT 2 R Ϫ/Ϫ / ApoE Ϫ/Ϫ double-knockout mice eating a high-fat diet display exacerbated atherosclerotic lesions and/or lesion development. 47, 48 Conversely, there are also studies 49 -51 that have suggested no protective role for the AT 2 R in atherosclerosis. Recently, Dandapat and colleagues 52 reported that vascular overexpression of AT 2 R in mice decreased atherosclerotic lesion formation by decreasing collagen accumulation and pro-oxidant signals. In the current study, it appears that Ang (1-7) is able to mediate at least some of its vasoprotective and atheroprotective effects via the AT 2 R, thus suggesting that under some circumstances, Ang (1-7) may act as an endogenous AT 2 R agonist, as previously reported. 24, 8 On the other hand, to our knowledge, the current study is the first demonstration of long-term Ang (1-7) treatment exerting atheroprotection in ApoE Ϫ/Ϫ mice via the MasR, which is consistent with it inhibiting neointimal formation in stent-implanted rats 20 and improving endothelial function in Wister rats. 21 Interestingly, both AT 2 R and MasR blockade attenuated the response mediated by Ang (1-7) to a similar extent. As already outlined, there are many instances 32, 34, 36, 45, 46 of receptor promiscuity for Ang (1) (2) (3) (4) (5) (6) (7) in that this peptide was inhibited individually by either MasR, AT 2 R, or AT 1 R blockade or by combinations of these antagonists. On this latter point, the current study would suggest that the inhibition of either MasR or AT 2 R was sufficient to dampen Ang (1-7) signaling, which implies some cross talk between these receptors, as previously noted. 32, 34, 36, 45, 46 Alternatively, it is possible that AT 2 R blockade by PD123319 has redirected endogenous Ang II toward further activation of the AT 1 R, thus overcoming the protective effects mediated by Ang (1-7) acting at the MasR. Another possibility is that the effects of PD123319 were nonspecific against the MasR.
Researchers 10, 11, 48, 51, 53 have demonstrated increases in AT 1 R, AT 2 R, and ACE2 immunoreactivity in atherosclerotic vessels. We confirmed these findings in the current study, as
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well as increased MasR immunoreactivity in thoracoabdominal aortic cross sections (data not shown). Given that ACE2 readily converts Ang II to Ang (1-7) and that there are increased tissue ACE2 levels, it is feasible that local production of Ang (1-7) contributes to the regulation of vascular disease. We did not measure tissue Ang (1-7) levels; basal plasma Ang (1-7) levels were similar to those recently reported in rats, in which measurements occurred by the same method. 54 Plasma peptide levels in our study did not change after long-term subcutaneous Ang (1-7) treatment. In contrast, there was a marked elevation of the plasma Ang (1-7) level after intravenous administration in rats, 26 which suggests that route of administration and/or species may contribute to this discrepancy. Alternatively, unchanged plasma levels may reflect greater metabolism of infused peptides in mice than in rats. In any case, systemic Ang (1-7) may be atheroprotective by increasing local tissue levels of Ang (1-7); however, this theory awaits confirmation.
In conclusion, we have reported novel Ang (1-7)-evoked vasoprotection and antiatherosclerotic effects. These effects appear to be dependent on elevated NO bioavailability because eNOS protein levels and immunoreactivity were increased and superoxide levels were concomitantly reduced. To our knowledge, this is the first study presenting the atheroprotective effects of Ang (1-7) involving complex interactions between AT 2 R and MasR, which have previously been reported. 32, 34, 36, 45, 46 The increased NO bioavailability mediated by the AT 2 R/MasR axis is an important therapeutic target for vasoprotection and atheroprotection.
